Daclatasvir
Y. Vivian Tsai, Pharm.D., Paul G. Auwaerter, M.D.
INDICATIONS
INDICATIONS
INDICATIONS
WHO
WHO
- In combination with sofosbuvir for the treatment of chronic HCV infection, genotypes 1–6.
- WHO recommends SOF/DCV as a pangenotypic regimen for adults, adolescents, and children ≥3 years.
- The original branded product is no longer marketed in the U.S.
- Daclatasvir remains widely used internationally as a generic.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.